Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Dynamic Contents for LPBI Group’s PowerPoint Presentation

 

The source material used in the creation of LPBI Group’s PowerPoint Presentation is from

• Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/

WORK-in-PROGRESS

 

Challenges and Opportunities for Curated, Scientific Content

Two Strategic Structural Holes:

• Digital information explosion in the fields of Life Sciences and Medicine
• High rate of information obsolescence in the fields of Life Sciences and Medicine

 

Opportunities: Many Convergent Domains for Curated, Scientific Content

• Significant amount of information collected on all disease states
• Accessibility of information updated in real-time for scientists and non-scientists
• Vast knowledge database on medicine and technology
• Valuable information for training and education development in medical schools

 

The LPBI Group Business Model

Vision

Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing

LOB – Line of Business

Three Interrelated Domains

1. Open Access online scientific journal
2. BioMed e-Series; e-Books on Amazon
3. Real-time press coverage of BioTech Global Premier Conferences

 

Competitive Advantage

Interrelated Domains

1. 1. Open Access online scientific journal
   2. BioMed e-Series; e-Books on Amazon

• Each e-book has an abbreviated electronic table of contents which consists of live links from each article in an e-book to the article in the journal.
• Readers of the e-books click on the link and get the most updated “State of Science” for each topic in the e-books.

Which make the e-book alive and an up-to-date source of knowledge

Unique Format of Managing Conference

1. Part One: The Process of Real Time Coverage using Social Media
2. Part Two: List of BioTech Conferences 2013 to Present
3. Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

Benefits for The Ecosystem

• The material produced is transformative because it makes cutting-edge biomedical research innovation widely available to the non-research community.
• The method of curation as scientific communication includes:

• Experts, authors, writers add their depth of knowledge on subjects to the breadth of materials selected by their expertise to form new curations or updating existing ones.
• The books are transformative in their capacity to accelerate diffusion of scientific innovations.
• The curation is done by experts with a perspective on the field, allowing for the creation of the scientific context that unifies conceptual evolution with the breakthrough analyzed in the curation and the future implications to be anticipated.

Technology

• The books include medical science, diagnostics and therapy. Their sustainability is maintained by:
  • Online continuing updates made to articles in the journal.
  • Each e-book has an abbreviated electronic table of contents which consists of live links from each article in an e-book to the article in the journal. Readers of the e-books click on the link and get the most updated “State of Science” for each topic in the e-books.
    • Which make the e-book alive and an up-to-date source of knowledge.
  • “Journal Ontology” is a relational and hierarchical knowledge base allowing for expansion of the content creation process on these two dimensions, but it is not limited to these two (articles in the Journal and articles in the e-Books).
    • For example: one of the research categories “Interviews with Scientific Leaders”, includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component, which is used extensively in the BioMed e-Series.

Summary: It makes all the curations available through open access

Business Development

• The collection of 5,273 articles (5,405 on 11/2/2018) has a potential to further constitute an “Intellectual Property Vault”, which:
• Has the potential of being used for creation of new titles for new e-books.
  • It is a reservoir of Ideas in the form of research categories populated by scientific curations.
• Online reach is growing and is driven by cutting edge subject matters added on a continuing basis to the Intellectual Property Vault.
• “Innovations in Drug Discovery” and “Drug Delivery” are covered in real time, on average up to 12 per year by Dr. Lev-Ari and other Team members attending Biotech and Medicine Conferences on press passes.
• In 2018, at least 10 “International Leading Breakthroughs in BioTechnology Conferences” will be covered in real time by Dr. Lev-Ari.

 

 

Image rendered by Amnon Danzig

The Business Landscape

Summary

The Curation as the new scientific Communication Method can solve the following challenges for the scientific community:

• Digital information explosion
• High rate of information obsolescence

 

 

 

Appendix

Statistics – Exposure

Accomplishment for the end of 2018

• 1,562,778 e-Readers @pharma_BI
  @AVIVA1950 393,431 views
  • https://lnkd.in/eEyn69r
• #Bundled #CVD #Diseases – 6 Volumes 
  • https://lnkd.in/e6WkMgF
• #Bundled #Cancer 1,2 #immunology 1,2,3 #PrecisionMedicine 1,2,3,4
  • https://lnkd.in/ekWGNqA

Exposure Statistics

• 5,405 (on 11/2/2018) articles that review biomedical research in an advanced curatorial style have been published with over 1,517,894 (on 11/2/2018) e-readers.
• In her active role as editor-in-chief, Dr. Lev-Ari has curated or co-curated 557 articles in 13 e-books (as of 3/30/2018).
• In 2018:
  • For BioMed’s e-Series Volume 14^th another 96 curations (66 as single author) and,
  • For BioMed’s e-Series Volume 15^th another 108 curations (56 as single author).
  • Several articles were selected by the Editor to be part of more than one volume in the 16-Volume BioMed e-Series
• These articles make biomedical research advances available online to medical students and health-care professionals, as well as graduate students in the biomedical sciences, and the interested public. She has assembled an impressive and highly motivated group of authors.
• In addition, the articles have stimulated a great number of interesting responses that are also available online to the readers of the books and articles published online by LPBI Group.

Website statistics

• Below are examples of the effect of Dr. Lev-Ari’s curation as measured by the number of electronic viewers. For all of them, Dr. Lev-Ari was either sole curator or had co-curators.
• Site statistics on 11/2/2018, # of e-Readers per selected list of articles:
  • “Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)” (12,901 viewers).
  • “Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care” (6,798 viewers).
  • “Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes” (1,983 viewers).
• Below are examples of the effect of Dr. Lev-Ari’s curation as measured by the number of electronic viewers. For all of them, Dr. Lev-Ari was either sole curator or had co-curators.
• Site statistics on 11/2/2018, # of e-Readers per selected list of articles:
  • “Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation” (1,115 viewers).
  • “Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes” (1,438 viewers).
  • “Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?” (1,524 viewers).
  • “Treatment of Refractory Hypertension via Percutaneous Renal Denervation” (1,087 viewers).

 

About LPBI Group, Director & Founder: Aviva Lev-Ari, PhD, RN

Short Bio

Earned BA, MA at HUJI, 1973,1976. Earned PhD’83 at University of California, Berkeley. After a twenty-year career as an executive in research and technology, 1985-2005, Dr. Lev-Ari re-invented herself and devoted her life to health care. She studied Biological Science at Northeastern University, then nursing and became a registered nurse in 2008. She was involved in cardiovascular research through pharmacological therapy while studying at Northeastern, during which she developed her skills at recognizing valuable and innovative research in pharmacotherapy. She worked in long-term post-acute settings in nursing management roles, which enabled her to see health care delivery from the patient’s perspective, as well.

Aviva’s achievement

• Lev-Ari’s work is innovative and creative.
  It has perfected the art of scientific curation for medical education of the cutting-edge literature.
• Lev-Ari has overseen and contributed many articles to the thirteen volumes, as the number, above in medicine and life sciences that LPBI Group has published as electronic books (e-books).
  It makes all the curations available through open access and uses attractive titles for all articles: for example, “Identification of Biomarkers that are Related to the Actin Cytoskeleton”.
• She has created hierarchical ontologies, with the help of medical experts.

https://pharmaceuticalintelligence.com/contributors-biographies/

As examples, the Journal published:

• 978 articles on “Cancer Biology & Innovations in Cancer Therapy”,
• 771 articles on “Frontiers in Cardiology and Cardiovascular Disorders”
• 654 articles on “Personalized and Precision Medicine & Genomics Research”
• 504 articles on “Cell Biology and Cell Circuits” that can be accessed at https://pharmaceuticalintelligence.com/

Justifications for 2018 Yidan Prize Nomination

• Lev-Ari in April 2012 launched PharmaceuticalIntelligence.com, an internet website as an educational Open Access online scientific journal. In October 2012, she launched a BioMed e-series of electronic books in Medicine and Life Sciences which use the Kindle direct publishing platform for book publishing by Amazon.com.
• The books evolved for six years from specifically identified topics in Medicine and Biomedical Sciences, including molecular biology, genomics, pharmaceutics and pathophysiology. There have been a number of contributors with the necessary professional competences.
• The work involved in the writing took many hundreds of hours of study and preparation. These sources have considerable electronic readership of 1,517,894 (on 11/2/2018) and have a potential for growing use in teaching of medical students, advanced undergraduate, and graduate students in medical sciences. Currently, two e-books are used in curriculum development in medical schools in the US. An outreach plan for deans of medical schools and oncologists and cardiologists in community hospitals and clinics is in the making.

Reflections on a Four-phase Career

Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:

1. Phase 1: Research, 1973 – 1983
2. Phase 2: Corporate Applied Research in the US, 1985 – 2005
3. Phase 3: Career Reinvention in Health Care, 2005 – 2012
4. Phase 4: Electronic Scientific Publishing, 4/2012 to present

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Recollections of Years at UC, Berkeley, Part 1 and Part 2

• Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

 

• Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

 

Achievements in Three Academic Disciplines

• Pioneering implementations of Analytics to Business decision making

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence 

Digital KOL Parameters

Key Opinion Leader (KOL) – Aviva Lev-Ari, PhD, RN, as evidenced by

https://pharmaceuticalintelligence.com/2016/07/21/key-opinion-leader-kol-aviva-lev-ari-phd-rn-as-evidenced-by/

Medical Education Development: Content Creation in Five Specialties in Medicine and Life Sciences

• e-Books 1^st to 13^th are published on Amazon.com

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari